{"id":10595,"date":"2022-06-13T10:05:29","date_gmt":"2022-06-13T08:05:29","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=10595"},"modified":"2022-06-13T11:05:47","modified_gmt":"2022-06-13T09:05:47","slug":"imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/","title":{"rendered":"ImCheck annonce la cl\u00f4ture d\u2019un tour de financement de 96 millions d’euros (103 millions de dollars US) pour avancer la validation clinique de son anticorps activateur des lymphocytes T gamma-delta et acc\u00e9l\u00e9rer le d\u00e9veloppement de son pipeline disruptif en immuno-oncologie"},"content":{"rendered":"

ImCheck Therapeutics<\/a> a annonc\u00e9 aujourd’hui la cl\u00f4ture d\u2019un tour de financement de 96 millions d’euros (103 millions de dollars US), comprenant un tour de table de s\u00e9rie C de 80 millions d’euros (86 millions de dollars US) codirig\u00e9 par Earlybird et Andera Partners et de la conversion de la derni\u00e8re tranche de s\u00e9rie B en actions de s\u00e9rie C (16 millions d’euros – 17,2 millions de dollars US). Invus et la Leukemia and Lymphoma Society ont \u00e9galement rejoint le tour de table. Les investisseurs existants, dont le Growth Opportunity Fund de Kurma Partners, Eurazeo, Gimv, Pfizer Ventures, Bpifrance, Wellington Partners, Pureos Bioventures, Agent Capital et Alexandria Venture, ont particip\u00e9 \u00e0 l’op\u00e9ration. Avec une situation de tr\u00e9sorerie aujourd\u2019hui tr\u00e8s confortable, la soci\u00e9t\u00e9 renforce son leadership dans le domaine des lymphocytes T gamma-delta.<\/p>\n

Les fonds seront prioritairement allou\u00e9s \u00e0 la poursuite de l\u2019essai clinique EVICTION qui \u00e9value actuellement ICT01, le candidat le plus avanc\u00e9 d’ImCheck, \u00e0 la fois en monoth\u00e9rapie et en combinaison avec un anti-PD-1 dans un large \u00e9ventail de tumeurs solides et h\u00e9matologiques. Ils permettront notamment de poursuivre la phase d\u2019expansion de l\u2019essai (Phase IIa) et \u00e0 aller au terme de l\u2019essai randomis\u00e9 contr\u00f4l\u00e9 en double aveugle contre placebo (Phase IIb). La Soci\u00e9t\u00e9 va \u00e9galement investir dans le d\u00e9veloppement clinique d’ICT01 en combinaison avec d’autres agents th\u00e9rapeutiques, y compris l’IL-2, dans le cadre du nouvel essai clinique EVICTION-2. Ce financement permettra en outre d\u2019acc\u00e9l\u00e9rer l\u2019entr\u00e9e en clinique d’autres anticorps de son portefeuille, en immuno-oncologie mais aussi dans les maladies auto-immunes et infectieuses. Il permettra \u00e9galement \u00e0 la Soci\u00e9t\u00e9 de renforcer ses \u00e9quipes d\u00e9di\u00e9es aux op\u00e9rations cliniques et aux affaires r\u00e9glementaires, en Europe comme aux \u00c9tats-Unis.<\/p>\n

\u00ab\u00a0Depuis sa cr\u00e9ation, ImCheck a b\u00e9n\u00e9fici\u00e9 du soutien d’un syndicat d\u2019investisseurs internationaux de premier plan. Sur un march\u00e9 financier tr\u00e8s tendu, nous avons r\u00e9ussi une lev\u00e9e cons\u00e9quente avec la participation de fonds strat\u00e9giques aux \u00c9tats-Unis comme en Europe. Nous sommes aujourd\u2019hui dans les meilleures conditions pour d\u00e9livrer les immenses promesses de notre portefeuille d\u2019anticorps th\u00e9rapeutiques \u00bb, <\/em>a d\u00e9clar\u00e9 <\/strong>Pierre d\u2019Epenoux<\/strong><\/a>, pr\u00e9sident d’ImCheck Therapeutics. <\/strong>\u00ab\u00a0La position d\u2019ImCheck est unique et exclusive sur toute la superfamille des butyrophilines. Elles permettent l\u2019immunomodulation des cellules du syst\u00e8me immunitaire inn\u00e9 et adaptatif, qui pourrait \u00eatre cl\u00e9 dans le traitement de nombreuses pathologies. Nous sommes ravis de b\u00e9n\u00e9ficier aujourd\u2019hui du soutien de la US Leukemia and Lymphoma Society, la plus grande association de patients d\u00e9di\u00e9e \u00e0 la lutte contre les cancers h\u00e9matologiques.\u00a0\u00bb<\/em><\/p>\n

\u00c0 l’occasion de ce tour de financement, Florent Gros (Earlybird) et Rapha\u00ebl Wisniewski (Andera Partners) rejoignent le Conseil d’administration de la Soci\u00e9t\u00e9.<\/p>\n

Florent Gros, Partner chez Earlybird, commente,<\/strong> \u00ab\u00a0L’approche d’ImCheck en immuno-oncologie est tr\u00e8s diff\u00e9renci\u00e9e. Elle a d\u00e9montr\u00e9 dans ses essais cliniques sa capacit\u00e9 \u00e0 activer les lymphocytes T gamma-delta, un champ de l’immunoth\u00e9rapie \u00e0 fort potentiel et qui suscite un int\u00e9r\u00eat tr\u00e8s marqu\u00e9 dans la communaut\u00e9 biopharmaceutique. Chez Earlybird, nous soutenons les entreprises qui osent penser diff\u00e9remment et le concept innovant d’ImCheck en mati\u00e8re d’immunomodulation pourrait faire la diff\u00e9rence dans de nombreuses indications.\u00a0\u00bb<\/em><\/p>\n

Rapha\u00ebl Wisniewski, Partner chez Andera Partners, d\u00e9clare, <\/strong>\u00ab\u00a0Les inhibiteurs de points de contr\u00f4le immunitaire ont ouvert une nouvelle \u00e8re dans le traitement du cancer et ImCheck Therapeutics est \u00e0 l’avant-garde de la prochaine g\u00e9n\u00e9ration de ces immunoth\u00e9rapies. Nous avons suivi les avanc\u00e9es r\u00e9alis\u00e9es par l’\u00e9quipe dirigeante dans la mise en \u0153uvre de leur approche th\u00e9rapeutique visionnaire, bas\u00e9e sur les butyrophilines, que ce soit dans le d\u00e9veloppement pr\u00e9coce ou dans leur programme clinique \u00e0 haute valeur ajout\u00e9e. Chez Andera Partners, nous sommes convaincus que la Soci\u00e9t\u00e9 fera avancer sa technologie r\u00e9volutionnaire pour r\u00e9pondre aux besoins des patients dans une s\u00e9rie d’indications d’oncologie et potentiellement dans les maladies auto-immunes et infectieuses.\u00a0\u00bb<\/em><\/p>\n

L\u2019approche d\u2019immunoth\u00e9rapie d’ImCheck Therapeutics vise \u00e0 contourner les m\u00e9canismes de r\u00e9sistance de la tumeur au syst\u00e8me immunitaire en modulant l\u2019action d\u2019une toute nouvelle superfamille de points de contr\u00f4le immunitaire\u00a0: les butyrophilines (BTN). En retour, les BTN mobilisent \u00e0 leur tour un large \u00e9ventail de cellules immunitaires, notamment les lymphocytes T gamma-delta, les CD3, les CD8, les cellules NK et les macrophages, rassemblant ainsi les r\u00e9ponses immunitaires inn\u00e9es et adaptatives. Le vaste portefeuille d\u2019anticorps de la Soci\u00e9t\u00e9 repose sur l’immunomodulation des BTN et vise \u00e0 stimuler la r\u00e9ponse immunitaire dans les cancers ou les maladies infectieuses ou \u00e0 la r\u00e9duire dans les maladies auto-immunes.<\/p>\n

Hans Henrik Christensen, Directeur financier d\u2019ImCheck Therapeutics, ajoute<\/strong>, \u00ab\u00a0ImCheck a aujourd’hui lev\u00e9 154 millions d’euros au total. Gr\u00e2ce au soutien de nos investisseurs historiques et des nouveaux entrants, nous disposons d’un horizon de tr\u00e9sorerie jusqu’en 2026 nous permettant d’explorer le plein potentiel d\u2019ICT01. \u00bb<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

ImCheck Therapeutics a annonc\u00e9 aujourd’hui la cl\u00f4ture d\u2019un tour de financement de 96 millions d’euros (103 millions de dollars US), comprenant un tour de table de s\u00e9rie C de 80 millions d’euros (86 millions de dollars US) codirig\u00e9 par Earlybird et Andera Partners et de la conversion de la derni\u00e8re tranche de s\u00e9rie B en…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[78],"class_list":["post-10595","post","type-post","status-publish","format-standard","hentry","category-biodiscovery"],"acf":[],"yoast_head":"\nImCheck annonce la cl\u00f4ture d\u2019un tour de financement de 96 millions d'euros (103 millions de dollars US) pour avancer la validation clinique de son anticorps activateur des lymphocytes T gamma-delta et acc\u00e9l\u00e9rer le d\u00e9veloppement de son pipeline disruptif en immuno-oncologie - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImCheck annonce la cl\u00f4ture d\u2019un tour de financement de 96 millions d'euros (103 millions de dollars US) pour avancer la validation clinique de son anticorps activateur des lymphocytes T gamma-delta et acc\u00e9l\u00e9rer le d\u00e9veloppement de son pipeline disruptif en immuno-oncologie - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"ImCheck Therapeutics a annonc\u00e9 aujourd’hui la cl\u00f4ture d\u2019un tour de financement de 96 millions d’euros (103 millions de dollars US), comprenant un tour de table de s\u00e9rie C de 80 millions d’euros (86 millions de dollars US) codirig\u00e9 par Earlybird et Andera Partners et de la conversion de la derni\u00e8re tranche de s\u00e9rie B en...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-13T08:05:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-13T09:05:47+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"ImCheck annonce la cl\u00f4ture d\u2019un tour de financement de 96 millions d’euros (103 millions de dollars US) pour avancer la validation clinique de son anticorps activateur des lymphocytes T gamma-delta et acc\u00e9l\u00e9rer le d\u00e9veloppement de son pipeline disruptif en immuno-oncologie\",\"datePublished\":\"2022-06-13T08:05:29+00:00\",\"dateModified\":\"2022-06-13T09:05:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/\"},\"wordCount\":907,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/\",\"name\":\"ImCheck annonce la cl\u00f4ture d\u2019un tour de financement de 96 millions d'euros (103 millions de dollars US) pour avancer la validation clinique de son anticorps activateur des lymphocytes T gamma-delta et acc\u00e9l\u00e9rer le d\u00e9veloppement de son pipeline disruptif en immuno-oncologie - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2022-06-13T08:05:29+00:00\",\"dateModified\":\"2022-06-13T09:05:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImCheck annonce la cl\u00f4ture d\u2019un tour de financement de 96 millions d’euros (103 millions de dollars US) pour avancer la validation clinique de son anticorps activateur des lymphocytes T gamma-delta et acc\u00e9l\u00e9rer le d\u00e9veloppement de son pipeline disruptif en immuno-oncologie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImCheck annonce la cl\u00f4ture d\u2019un tour de financement de 96 millions d'euros (103 millions de dollars US) pour avancer la validation clinique de son anticorps activateur des lymphocytes T gamma-delta et acc\u00e9l\u00e9rer le d\u00e9veloppement de son pipeline disruptif en immuno-oncologie - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/","og_locale":"fr_FR","og_type":"article","og_title":"ImCheck annonce la cl\u00f4ture d\u2019un tour de financement de 96 millions d'euros (103 millions de dollars US) pour avancer la validation clinique de son anticorps activateur des lymphocytes T gamma-delta et acc\u00e9l\u00e9rer le d\u00e9veloppement de son pipeline disruptif en immuno-oncologie - ANDERA PARTNERS","og_description":"ImCheck Therapeutics a annonc\u00e9 aujourd’hui la cl\u00f4ture d\u2019un tour de financement de 96 millions d’euros (103 millions de dollars US), comprenant un tour de table de s\u00e9rie C de 80 millions d’euros (86 millions de dollars US) codirig\u00e9 par Earlybird et Andera Partners et de la conversion de la derni\u00e8re tranche de s\u00e9rie B en...","og_url":"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2022-06-13T08:05:29+00:00","article_modified_time":"2022-06-13T09:05:47+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"ImCheck annonce la cl\u00f4ture d\u2019un tour de financement de 96 millions d’euros (103 millions de dollars US) pour avancer la validation clinique de son anticorps activateur des lymphocytes T gamma-delta et acc\u00e9l\u00e9rer le d\u00e9veloppement de son pipeline disruptif en immuno-oncologie","datePublished":"2022-06-13T08:05:29+00:00","dateModified":"2022-06-13T09:05:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/"},"wordCount":907,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/","url":"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/","name":"ImCheck annonce la cl\u00f4ture d\u2019un tour de financement de 96 millions d'euros (103 millions de dollars US) pour avancer la validation clinique de son anticorps activateur des lymphocytes T gamma-delta et acc\u00e9l\u00e9rer le d\u00e9veloppement de son pipeline disruptif en immuno-oncologie - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2022-06-13T08:05:29+00:00","dateModified":"2022-06-13T09:05:47+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/fr\/imcheck-closes-upsized-eur-96-million-usd-103-million-financing-to-advance-clinical-validation-of-first-in-human-gamma-delta-2-t-cell-activating-antibody-and-accelerate-development-of-disruptive-imm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"ImCheck annonce la cl\u00f4ture d\u2019un tour de financement de 96 millions d’euros (103 millions de dollars US) pour avancer la validation clinique de son anticorps activateur des lymphocytes T gamma-delta et acc\u00e9l\u00e9rer le d\u00e9veloppement de son pipeline disruptif en immuno-oncologie"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/10595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=10595"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/10595\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=10595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=10595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}